"Just because we have the Geron technology, the Geron cells and some of the Geron people, don't expect us to look, smell or taste like the old Geron. That got dismembered by the board."
– Thomas Okarma, former Geron CEO, discussing the formation of BioTime Inc. subsidiary, Asterias Biotherapeutics Inc., which is purchasing Geron's embryonic stem cell assets

"We're getting to a tipping point where nanomedicine is going from an interesting technology to something that's being viewed as a here-and-now technology for the pharmaceutical industry."
– Scott Minick, president and CEO of BIND Therapeutics Inc., discussing the company's second major 2013 partnership, with Pfizer Inc., to develop its Accurin technology

"In order to solve the real health challenges of India's patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide."
– John Castellani, president and CEO of Pharmaceutical Research and Manufacturers of America, commenting on the Indian Supreme Court's ruling denying an appeal by Novartis AG, ending the company's 15-year quest for a patent for its cancer drug Gleevec/Glivec